Array BioPharma Inc. (ARRY) Analysts See $-0.22 EPS; Blackrock Muniholdings California Quality Fund (MUC) Has 1.47 Sentiment

April 17, 2018 - By Marguerite Chambers

Array BioPharma Inc. (NASDAQ:ARRY) Logo

Analysts expect Array BioPharma Inc. (NASDAQ:ARRY) to report $-0.22 EPS on May, 9.They anticipate $0.01 EPS change or 4.76% from last quarter’s $-0.21 EPS. After having $-0.17 EPS previously, Array BioPharma Inc.’s analysts see 29.41% EPS growth. The stock increased 3.53% or $0.53 during the last trading session, reaching $15.55. About 972,348 shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 68.58% since April 17, 2017 and is uptrending. It has outperformed by 57.03% the S&P500.

Blackrock Muniholdings California Quality Fund Inc (MUC) investors sentiment increased to 1.47 in Q4 2017. It’s up 0.09, from 1.38 in 2017Q3. The ratio is more positive, as 22 funds increased or started new positions, while 15 sold and decreased stock positions in Blackrock Muniholdings California Quality Fund Inc. The funds in our database reported: 3.94 million shares, up from 3.81 million shares in 2017Q3. Also, the number of funds holding Blackrock Muniholdings California Quality Fund Inc in top ten positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 11 Increased: 13 New Position: 9.

Since December 16, 2017, it had 0 buys, and 8 selling transactions for $15.94 million activity. Another trade for 819,671 shares valued at $8.90 million was made by Squarer Ron on Saturday, December 16. Shares for $278,210 were sold by VAN LUNSEN GIL J on Wednesday, January 17. Shares for $2.76 million were sold by Sandor Victor on Friday, March 9. The insider Robbins Andrew R sold $3.03M. Another trade for 7,500 shares valued at $102,975 was sold by Haddock Jason.

Investors sentiment increased to 1.3 in Q4 2017. Its up 0.09, from 1.21 in 2017Q3. It is positive, as 20 investors sold Array BioPharma Inc. shares while 50 reduced holdings. 27 funds opened positions while 64 raised stakes. 194.11 million shares or 1.73% more from 190.80 million shares in 2017Q3 were reported. Global X Management Com Lc stated it has 0% in Array BioPharma Inc. (NASDAQ:ARRY). State Of Wisconsin Investment Board owns 169,100 shares. Raymond James Fincl Advsr invested 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Federated Invsts Pa, Pennsylvania-based fund reported 1,103 shares. Moreover, Hollencrest Capital Mgmt has 0.24% invested in Array BioPharma Inc. (NASDAQ:ARRY). Kazazian Asset Lc owns 29,367 shares. Kennedy Capital Management has 309,188 shares. Victory Capital Management has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Ubs Asset Mgmt Americas stated it has 2.11M shares. Fmr Ltd Liability Com has 0.03% invested in Array BioPharma Inc. (NASDAQ:ARRY). Cambiar Invsts Limited Co owns 0.1% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 507,070 shares. California State Teachers Retirement System owns 313,829 shares for 0.01% of their portfolio. Nj State Employees Deferred Compensation Plan has invested 0.1% in Array BioPharma Inc. (NASDAQ:ARRY). Fincl Inv Mngmt Gru Limited, Michigan-based fund reported 220,806 shares. Tudor Et Al invested in 12,834 shares or 0% of the stock.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Array BioPharma had 37 analyst reports since June 3, 2016 according to SRatingsIntel. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Jefferies on Thursday, July 13. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Outperform” rating given on Monday, January 22 by Leerink Swann. The firm earned “Buy” rating on Tuesday, May 30 by Cantor Fitzgerald. On Wednesday, February 7 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Buy” rating by Piper Jaffray on Tuesday, February 6. Jefferies maintained the shares of ARRY in report on Thursday, August 24 with “Buy” rating. The firm has “Outperform” rating given on Wednesday, February 7 by Leerink Swann. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Overweight” rating by Cantor Fitzgerald on Monday, September 11. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Stifel Nicolaus on Friday, August 5. Cowen & Co maintained the stock with “Buy” rating in Sunday, January 21 report.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company has market cap of $3.23 billion. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. It currently has negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

The stock decreased 0.38% or $0.05 during the last trading session, reaching $13.11. About 49,338 shares traded. BlackRock MuniHoldings California Quality Fund, Inc. (MUC) has declined 7.45% since April 17, 2017 and is downtrending. It has underperformed by 19.00% the S&P500.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.